Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

por Falkenius, Johan, Johansson, Hemming, Tuominen, Rainer, Frostvik Stolt, Marianne, Hansson, Johan, Egyhazi Brage, Suzanne
Publicado 2017

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma

por Costa Svedman, Fernanda, Das, Ishani, Tuominen, Rainer, Darai Ramqvist, Eva, Höiom, Veronica, Egyhazi Brage, Suzanne
Publicado 2022

Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer

por Hjerpe, Elisabet, Egyhazi Brage, Suzanne, Carlson, Joseph, Frostvik Stolt, Marianne, Schedvins, Kjell, Johansson, Hemming, Shoshan, Maria, Åvall-Lundqvist, Elisabeth
Publicado 2013

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

por Das, Ishani, Wilhelm, Margareta, Höiom, Veronica, Franco Marquez, Rodolfo, Costa Svedman, Fernanda, Hansson, Johan, Tuominen, Rainer, Egyhàzi Brage, Suzanne
Publicado 2019

Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

por Das, Ishani, Chen, Huiqin, Maddalo, Gianluca, Tuominen, Rainer, Rebecca, Vito W., Herlyn, Meenhard, Hansson, Johan, Davies, Michael A., Egyházi Brage, Suzanne
Publicado 2020

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma

por Das, Ishani, Gad, Helge, Bräutigam, Lars, Pudelko, Linda, Tuominen, Rainer, Höiom, Veronica, Almlöf, Ingrid, Rajagopal, Varshni, Hansson, Johan, Helleday, Thomas, Egyházi Brage, Suzanne, Warpman Berglund, Ulrika
Publicado 2020

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

por Vidarsdottir, Linda, Fernandes, Rita Valador, Zachariadis, Vasilios, Das, Ishani, Edsbäcker, Elin, Sigvaldadottir, Ingibjorg, Azimi, Alireza, Höiom, Veronica, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Pokrovskaja Tamm, Katja
Publicado 2020

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

por Azimi, Alireza, Tuominen, Rainer, Costa Svedman, Fernanda, Caramuta, Stefano, Pernemalm, Maria, Frostvik Stolt, Marianne, Kanter, Lena, Kharaziha, Pedram, Lehtiö, Janne, Hertzman Johansson, Carolina, Höiom, Veronica, Hansson, Johan, Egyhazi Brage, Suzanne
Publicado 2017

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

por Azimi, Alireza, Caramuta, Stefano, Seashore‐Ludlow, Brinton, Boström, Johan, Robinson, Jonathan L, Edfors, Fredrik, Tuominen, Rainer, Kemper, Kristel, Krijgsman, Oscar, Peeper, Daniel S, Nielsen, Jens, Hansson, Johan, Egyhazi Brage, Suzanne, Altun, Mikael, Uhlen, Mathias, Maddalo, Gianluca
Publicado 2018

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

por Vidarsdottir, Linda, Azimi, Alireza, Das, Ishani, Sigvaldadottir, Ingibjorg, Suryo Rahmanto, Aldwin, Petri, Andreas, Kauppinen, Sakari, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Frostvik Stolt, Marianne, Tuominen, Rainer, Sangfelt, Olle, Pokrovskaja Tamm, Katja, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Johnsson, Per
Publicado 2021